Insomnia| A Pipeline Analysis Report 2018| Technavio
LONDON--(BUSINESS WIRE)--Jul 6, 2018-- has announced its pipeline analysis report on the . The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat insomnia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180706005370/en/
Technavio has published a new report on the drug development pipeline for insomnia, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market.
Insomnia: Market overview
Insomnia, a type of sleep disorder, is a medical condition of sleeplessness. Long sleep latency, frequent night-time awakenings, or delayed sleep time are some of the symptoms of insomnia. Factors such as high level of stress, emotional disorders, sedentary lifestyle, certain medical conditions, and financial distress might cause this sleeping disorder.
According to a senior analyst at Technavio for infectious and rare diseases , “There are several symptoms of insomnia, including difficulty falling asleep at night, waking up during the night, daytime tiredness or sleepiness, increased errors or accidents, and ongoing worries about sleep. According to a major research, normal adults require at least 7 hours of sleep every night. Short-term rest is characterized as under seven hours of rest for every 24-hour time frame.”
Insomnia: Segmentation analysis
This market research report segments the insomnia market based on therapies employed (monotherapy, combination therapy, and unknown), RoA (oral, inhalation, and unknown), therapeutic modalities (small molecule, protein, and unknown), targets for drugs under development (GABA receptor, orexin receptor, melatonin receptor, and unknown), MoA (dual orexin receptor antagonist, orexin OX2 agonist, melatonin agonist, GABA receptor modulator, and unknown), and recruitment status (recruiting, not yet recruiting, completed, and unknown).
Monotherapy includes the use of a single drug to treat a disorder or a disease. In the current pipeline, around 69% of the molecules that are being investigated for the treatment of insomnia are monotherapy.
In case of oral RoA, the delivery of the drug substances is done through the mouth cavity. More than 81% of the total molecules that are in the current pipeline are expected to be administered orally.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development LandscapeDrugs under development Indications coverage
Drug Development StrategiesTherapies employed RoA Therapeutic modality Geographical coverage
Recruitment StrategiesRecruitment status Gender Age Recruitment volume
Key CompaniesType of players Company Overview
Discontinued or Dormant Molecules
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180706005370/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL RESEARCH SCIENCE GENERAL HEALTH
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 07/06/2018 01:46 PM/DISC: 07/06/2018 01:46 PM